



# Central Florida Retina

## John C. Olson, M.D.

### EDUCATION

|      |   |             |
|------|---|-------------|
| M.D. | Honors Program in Medical Education<br>Northwestern University<br>Chicago, Illinois | March, 1977 |
| B.S. | Northwestern University<br>Chicago, Illinois  | June, 1975  |

### FELLOWSHIP, RESIDENCY, INTERNSHIP

|                           |  |             |
|---------------------------|--|-------------|
| Vitreoretinal Fellowship: | Bascom Palmer Eye Institute<br>University of Miami<br>Miami, Florida | 1981 - 1982 |
| Ophthalmology Residency:  | University of Texas<br>Health Science Center<br>Dallas, Texas        | 1978 - 1981 |
| Internship (Rotating):    | University of Texas<br>Health Science Center<br>Dallas, Texas        | 1977 - 1978 |

### MEDICAL PRACTICE

|   |  |                |
|---|--|----------------|
| Central Florida Retina<br>3824 Oakwater Circle<br>Orlando, FL 32806 | Diseases & Surgery of the<br>Retina and Vitreous | 1982 - Present |
|---|--|----------------|

### HOSPITAL APPOINTMENTS

|  |                |
|--|----------------|
| Active, Ophthalmology:<br>Orlando Regional Health System, Orlando, Florida | 1982 - Present |
| Advent Health, Orlando, Florida  | 1983 - Present |
| Orlando Ophthalmology Surgery Center, Orlando, Florida                     | 2003 - Present |



## ACADEMIC APPOINTMENTS

Assistant Professor of Ophthalmology  
College of Medicine  
University of Central Florida  
Orlando, Florida

2010 - present

## CERTIFICATION

American Board of Ophthalmology

December, 1982

## LICENSURE

Texas  
Florida

February, 1978  
May, 1981

## MEDICAL SOCIETIES

Florida Society of Ophthalmology  
American Academy of Ophthalmology  
American Society of Retina Specialists

## PRESENTATIONS

1. Olson, John C.:  
Results of Resident Intraocular Lens Surgery  
Veterans Administration Hospital, Dallas, Texas  
Presented at the University of Texas Health Science Center  
Resident and Alumni meeting, Dallas, Texas, June 1981
2. Olson, John C.:  
Results in the treatment of Postoperative Endophthalmitis  
Presented at the 87 Annual Meeting of the American Academy of  
Ophthalmology, San Francisco, California,  
October 30-November 5, 1982
3. Olson, John C.:  
Update on Endophthalmitis  
Presented at the American Academy of Ophthalmology,  
Southern Regional Update Course, Miami, Florida,  
March 4, 1989
4. Olson, John C.:  
Retinal Hemorrhages as a Consequence of Epidural Steroid Injection  
Presented at the Bascom Palmer Eye Institute  
Anniversary Meeting in Honor of Donald Gass, M.D.,  
Miami, Florida, May, 1995




## PUBLICATIONS

1. Olson JC, Flynn HW, Jr, Forster RK, Culbertson WW. Results in the treatment of postoperative endophthalmitis. *Ophthalmology*. 1983;90(6):692–699.
2. Kushner, FH, Olson, JC. Retinal Hemorrhage as a Consequence of Epidural Steroid Injection. *Arch Ophthalmology*. 1995;113: 309-313.
3. Shaikh S, Ho S, Richmond PP, Olson JC, Barnes CD. Untoward Outcomes in 25-Gauge versus 20-Gauge Vitreoretinal Surgery. *Retina* 2007;27(8): 1048-1053.
4. Shaikh S, Olson JC, Richmond PP. Retinal Pigment Epithelial Tears after Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration. *Indian J Ophthalmol*. 2007 Nov-Dec;55(6):470-2.
5. Griffen D, Richmond PP, Olson JC. Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration. *Journal of Ophthalmology*. 2014 Nov 20 (2014): 1-6.

## RESEARCH

1. Miravant - Protocol #SnET2-98EA001; Principal Investigator  
A Phase III Randomized, Parallel-Group, Multicenter Study to Observe Lesion Response Efficacy over a 2-Year Study Period with SnET2-PDT Treatment of Subfoveal CNV Secondary to Age-Related Macular Degeneration.
2. New England Eye Center, Tufts University: TTT 4CNV; Principal Investigator  
Transpupillary Thermal Therapy in Age-Related Macular Degeneration.
3. Novartis Pharmaceutical - Protocol #CSMS995 0804; Principal Investigator  
A Phase II Randomized, Double-Masked, Controlled Study to Evaluate the Safety and Efficacy of Sandostatin (Octreotide) in Patients with Diabetic Macular Edema.
4. Alimera (FAME); Principal Investigator  
A Phase II Randomized, Double Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema.
5. Regeneron (VIEW); Principal Investigator  
A Phase III Randomized, Double Masked, Active Controlled Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration.
6. Regeneron (VISTA) Protocol VGFT-OD-1009 DME; Principal Investigator  
A Double-Masked, Randomized, Active-Controlled, Phase III Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema.
7. Genentech; Protocol #FVF2587g ANCHOR; Sub-Investigator  
A Phase III Study which compares efficacy of subjects who have Lucentis®, injected into the eye once a month for two years, to PDT (Visudyne®), administered to the eye every three months for two years in patients with wet Age-Related Macular Degeneration (AMD).



## RESEARCH (cont.)

8. Genentech; Protocol #FVF3192g PIER; Sub-Investigator  
Age-Related Macular Degeneration Study.
9. DRCR network; Sub-Investigator  
A Phase II Study for Evaluation of Bevacizumab (Avastin) Intravitreal Injections in Subjects with Diabetic Macular Edema.
10. VERTACL Study; Sub Investigator  
A Phase II/III Multi-Center, Randomized, Clinical Trial to evaluate the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants with Neovascular Age-Related Macular Degeneration (AMD).
11. National Eye Institute: (SCORE) Study; Sub-Investigator  
Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion.
12. Alcon/Novartis; Sub-Investigator  
A Phase III Randomized, Parallel-Group, Multicenter, Double-Masked Study of the Safety and Efficacy of Anecortave Acetate for Depot Suspension (15mg and 30 mg) Versus Sham Administration in Arresting the Progression of Non-Exudative (dry) AMD in Patients who are at Risk for Progressing to Exudative (wet) AMD.

## MISCELLANEOUS

Volunteer Medical Mission  
Project ORBIS  
Arequipa, Peru, 1983

Grace Medical Home  
Volunteer Physician  
Orlando, Florida, 2011 - present

